spacer
home > ebr > summer 2004 > functional genomics in trypanosomes: using rna interference to assign gene function and validate drug targets in tropical disease agents
PUBLICATIONS
European Biopharmaceutical Review

Functional Genomics in Trypanosomes: Using RNA Interference to Assign Gene Function and Validate Drug Targets in Tropical Disease Agents

The World Health Organization has designated many tropical protozoan pathogens as high priority re-emergent disease agents. Asymmetric funding - many of these pathogens affect citizens of countries with low or no economic wealth - has meant that the development of new therapeutics is slow or non-existent. For researchers interested in Trypanosoma brucei, the causative agent of human African sleeping sickness, a combination of renewed interest, completion of the genome project and RNA interference technology may herald a new period of advance in both therapeutic development and understanding of basic biology. Can the research community deliver?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Mark C Field, Department of Biological Sciences at Imperial College, London, and Dr Mark Carrington, Department of Biochemistry at the University of Cambridge, UK

Dr Mark C Field is at the Department of Biological Sciences, Imperial College. He was educated at Oxford Univeristy and completed his doctoral work there at the Glycobiology Institute on glyoprotein structure and function. His postdoctoral career began in the US where he started to work on trypanosomatids at the Rockefeller and Stanford Universities, as well as a short period at Genentech Inc. In 1994, he established his own research group at Imperial College, London, which focuses on the molecular cell biology of Trypanosoma brucei.


Dr Mark Carrington is at the Department of Biochemistry, University of Cambridge. He was educated at Cambridge, obtaining his PhD in Plant Molecular Biology. He has worked on trypanosomes since the start of his postdoctoral career and has extensive experience in the study of protein structure and RNA processing, and is interested in the development of therapeutics based on surface proteins and on host-resistance mechanisms.

spacer
Dr Mark C Field
spacer
spacer
spacer
Dr Mark Carrington
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing the new Rapidox 7100

When dealing with volatile applications such as those within chemical and combustion processes, you need a high specification instrument you can trust; the Rapidox 7100 Multigas Analyser is that instrument
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement